Cardiac MRI Identified Rare Heart Amyloid Pattern

A new case study highlights how MRI imaging detected amyloidosis that a standard nuclear scan missed.

Updated on Oct. 9, 2026 in Heart Disease

Isometric editorial illustration of a stylized heart muscle cross-section in shades of oxblood, representing diagnostic medical imaging of amyloidosis. — A case report from Allegheny General Hospital highlights how cardiac MRI imaging successfully identified ATTR-CM amyloid deposits that were missed by standard nuclear scans. AI Illustration. Upload story photo >

Live Poll

Would you seek a second opinion if a medical test was negative but symptoms persisted?

In September 2026, a case report detailed how a 74-year-old man with heart failure was diagnosed with wild-type ATTR-CM after a cardiac MRI revealed localized muscle thickening. The imaging identified a donut-shaped ring of amyloidosis that had initially produced a false-negative result on a standard nuclear scan.

Why it matters

Early diagnosis of cardiac amyloidosis is often delayed because initial nuclear scans can fail to detect patchy deposits. This case underscores the importance of using multi-modal imaging to identify specific structural patterns in patients presenting with heart failure, atrial fibrillation, and carpal tunnel syndrome.

A cardiac MRI showed a 19-millimeter thick ring of muscle at the base of the left ventricle with 38 percent extracellular volume. Following treatment with 61 mg of tafamidis, the patient showed improved blood markers.

The players

Allegheny General Hospital

This Pittsburgh-based medical center served as the site where the clinical diagnosis and follow-up treatment occurred.

The details

Doctors at Allegheny General Hospital used 3D nuclear imaging to confirm the presence of amyloid deposits after the MRI provided the initial clue. The patient received a diagnosis of wild-type ATTR-CM, a condition where proteins build up in the heart muscle and impair function.

2019: FDA approved tafamidis for cardiac amyloidosis.
2024: FDA approved acoramidis for ATTR-CM.
2025: FDA approved vutrisiran for ATTR-CM.
September 2026: Case report published in JACC: Case Reports.

Health Landscape

This case study updates clinical diagnostic understanding by mirroring patterns observed in the 632 patients enrolled in the ATTRibute-CM trial. It highlights how refined imaging protocols can identify patients who might otherwise be missed by standard diagnostic criteria.

Patients presenting with recurring heart failure symptoms or bilateral carpal tunnel syndrome may benefit from asking physicians about advanced imaging options beyond initial nuclear scans. These diagnostic improvements can lead to earlier access to FDA-approved therapies that significantly lower cardiac stress markers.

The takeaway

Early detection of cardiac amyloidosis remains a clinical challenge that requires combining multiple imaging technologies to avoid false negatives. Improved diagnostic accuracy allows for the earlier initiation of specialized treatments like tafamidis, which can effectively reduce heart stress indicators.